Aadi Bioscience, Inc.

NasdaqCM AADI

Aadi Bioscience, Inc. Price to Book Ratio (P/B) on January 14, 2025: 0.86

Aadi Bioscience, Inc. Price to Book Ratio (P/B) is 0.86 on January 14, 2025, a 167.50% change year over year. Price to book ratio compares the stock price to the book value per share; above 1 indicates market values company more than its book value.

Aadi Bioscience, Inc. 52-week high Price to Book Ratio (P/B) is 1.28 on January 07, 2025, which is 48.46% above the current Price to Book Ratio (P/B).
Aadi Bioscience, Inc. 52-week low Price to Book Ratio (P/B) is 0.31 on January 17, 2024, which is -63.76% below the current Price to Book Ratio (P/B).
Aadi Bioscience, Inc. average Price to Book Ratio (P/B) for the last 52 weeks is 0.48.

Key data

Date	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield	Price to Earnings Ratio (P/E)

NasdaqCM: AADI

Aadi Bioscience, Inc.

CEO	Mr. David J. Lennon Ph.D.
IPO Date	Feb. 16, 2018
Location	United States
Headquarters	17383 Sunset Boulevard
Employees	53
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.

Key trends

Past 5 years